Genelux Corp
GNLX
Company Profile
Business description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Contact
2625 Townsgate Road
Suite 230
Westlake VillageCA91361
USAT: +1 805 267-9889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 21.50 | -0.24% |
| CAC 40 | 8,217.76 | 19.67 | -0.24% |
| DAX 40 | 25,063.12 | 170.92 | 0.69% |
| Dow JONES (US) | 49,296.62 | 165.46 | -0.33% |
| FTSE 100 | 10,047.56 | 75.17 | -0.74% |
| HKSE | 26,458.95 | 251.50 | -0.94% |
| NASDAQ | 23,586.27 | 39.10 | 0.17% |
| Nikkei 225 | 51,961.98 | 556.10 | -1.06% |
| NZX 50 Index | 13,715.02 | 51.44 | 0.38% |
| S&P 500 | 6,945.10 | 0.28 | 0.00% |
| S&P/ASX 200 | 8,695.60 | 27.90 | -0.32% |
| SSE Composite Index | 4,085.77 | 2.10 | 0.05% |